Serious risks noted in FDA labeling include: Boxed warning for thyroid C-cell tumors (observed in rodents) Pancreatitis Diabetic retinopathy complications Hypoglycemia (when combined with insulin or sulfonylureas) Acute kidney injury Gallbladder disease Full safety information is available in the Ozempic prescribing information
What TRANSCEND-T2D-1 doesn't capture is body composition quality: did the 16.8% reduction preserve lean mass, or does the triple agonist pathway sustain FFM protection seen with dual incretins
NatureM.D
Dosing and Administration# Liraglutide# Saxenda (obesity) : Start 0.6 mg daily, titrate weekly by 0.6 mg to 3.0 mg daily (5-week titration) Victoza (T2D) : Start 0.6 mg daily, increase to 1.2 mg, max 1.8 mg daily Subcutaneous injection, abdomen/thigh/upper arm Any time of day, with or without food No oral weight management formulation Semaglutide# Wegovy (obesity) : Start 0.25 mg weekly, titrate monthly to 2.4 mg weekly (16-week titration) Ozempic (T2D) : Start 0.25 mg weekly, titrate to 0.5 mg, max 2.0 mg weekly Rybelsus (T2D) : 3 mg daily oral for 30 days, then 7 mg, max 14 mg Oral semaglutide 25 mg (approved 2025): Oral formulation for weight management Weekly injection or daily oral tablet
doi: 10.1016/j.obpill.2024.100121 30
